Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terence W Friedlander

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
Pharmacology & Therapeutics|December 24, 2013
Looking back, to the future of circulating tumor cellsTerence W Friedlander, Gayatri Premasekharan, Pamela L Paris
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Conceptual Framework for Therapeutic Development Beyond Anti-PD-1/PD-L1 in Urothelial CancerPetros Grivas, Alexandra Drakaki, Terence W Friedlander, et al.
Plos One|November 16, 2017
Copy number gains at chr3p25 and chr11p11 are associated with lymph node involvement and survival in muscle-invasive bladder tumorsKarla J Lindquist, Thomas Sanford, Terence W Friedlander, et al.
Clinical Genitourinary Cancer|December 19, 2023
Central Nervous System Disease Progression Among Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Case SeriesChase Shipp, Tanya Jindal, Jonathan Chou, et al.
Journal for Immunotherapy of Cancer|January 26, 2018
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyondJason Zhu, Andrew J Armstrong, Terence W Friedlander, et al.
Journal of Racial and Ethnic Health Disparities|February 21, 2020
The Problem of Underrepresentation: Black Participants in Lifestyle Trials Among Patients with Prostate CancerKyle B Zuniga, Hala Borno, June M Chan, et al.
Urologic Oncology|October 2, 2010
Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II studyTerence W Friedlander, Vivian K Weinberg, Eric J Small, et al.
The Oncologist|March 1, 2018
A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate CancerXiao X Wei, Adam P Siegel, Rahul Aggarwal, et al.
International Journal of Cancer|October 30, 2013
Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancerTerence W Friedlander, Vy T Ngo, Huan Dong, et al.
Oncology Reports|October 6, 2011
A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancerTerence W Friedlander, Vivian K Weinberg, Yong Huang, et al.
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Pharmacology & Therapeutics|December 24, 2013
Looking back, to the future of circulating tumor cellsTerence W Friedlander, Gayatri Premasekharan, Pamela L Paris
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Conceptual Framework for Therapeutic Development Beyond Anti-PD-1/PD-L1 in Urothelial CancerPetros Grivas, Alexandra Drakaki, Terence W Friedlander, et al.
Plos One|November 16, 2017
Copy number gains at chr3p25 and chr11p11 are associated with lymph node involvement and survival in muscle-invasive bladder tumorsKarla J Lindquist, Thomas Sanford, Terence W Friedlander, et al.
Clinical Genitourinary Cancer|December 19, 2023
Central Nervous System Disease Progression Among Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Case SeriesChase Shipp, Tanya Jindal, Jonathan Chou, et al.
Journal for Immunotherapy of Cancer|January 26, 2018
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyondJason Zhu, Andrew J Armstrong, Terence W Friedlander, et al.
Journal of Racial and Ethnic Health Disparities|February 21, 2020
The Problem of Underrepresentation: Black Participants in Lifestyle Trials Among Patients with Prostate CancerKyle B Zuniga, Hala Borno, June M Chan, et al.
Urologic Oncology|October 2, 2010
Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II studyTerence W Friedlander, Vivian K Weinberg, Eric J Small, et al.
The Oncologist|March 1, 2018
A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate CancerXiao X Wei, Adam P Siegel, Rahul Aggarwal, et al.
International Journal of Cancer|October 30, 2013
Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancerTerence W Friedlander, Vy T Ngo, Huan Dong, et al.
Oncology Reports|October 6, 2011
A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancerTerence W Friedlander, Vivian K Weinberg, Yong Huang, et al.
Pageof 5